NASDAQ: GUTS · Industrial Applications and Services · 8 alerts · CIK 1572616
Share price
$0.9918Close, Nov 16
Market cap
$13.2M
Shares outstanding
13.26MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Fractyl Health, Inc. filings on SEC EDGAR ↗
Fractyl Health reported a net loss of $30.5 million for the first nine months of 2026, a significant improvement from the $97.2 million loss in the prior year period, primarily driven by a $29.1 million gain from the change in fair value of warrant liabilities. The company implemented a strategic reprioritization in October 2026, including a workforce reduction, to extend its financial runway as cash and cash equivalents decreased to $31.5 million from $81.5 million at year-end 2025.
Fractyl Health reported Q3 2026 financial results and announced a major strategic pivot to focus on its Revita program, including a 45% workforce reduction and the discontinuation of internal Rejuva development. The company reported positive six-month pivotal data from its REMAIN-1 trial and plans to submit an FDA De Novo marketing application in late Q4 2026.
Term
Q3 2026
“There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance.”
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
“Armed with positive data, we have focused the Company around Revita’s post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”
Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
Fractyl Health appointed Michael Wartell as an independent Class III director, increasing the board size to ten members. Mr. Wartell will receive cash compensation of $40,000 per month and will not participate in the company's standard Non-Employee Director Compensation Policy. He brings over 35 years of experience in opportunistic credit and special situations to the board.
Fractyl Health is implementing a strategic reprioritization to focus on its Revita program, resulting in a 45% workforce reduction and the discontinuation of its Rejuva gene therapy program. The company expects to incur $2 million in severance charges while extending its cash runway into Q2 2027 and reducing quarterly cash burn by approximately 50%.